dalteparin has been researched along with Acute Myelogenous Leukemia in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akram, J | 1 |
| Josefsson, P | 1 |
| Rømeling, F | 1 |
1 other study available for dalteparin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
[Necrotizing tonsillitis and renal vein thrombosis due to acute myeloid leukaemia].
Topics: Adult; Antineoplastic Agents; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Le | 2012 |